Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.73 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162806 | 1.00 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL7962292 | 1.00 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL27738090 | 0.87 | CYP3A4 (0.90) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL28093400 | 0.85 | CYP3A4 (0.93) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| D-Histidine SCHEMBL288043 | 0.84 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL19974306 | 0.84 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL388560 | 0.84 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL3260 | 0.84 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5497653 | 0.84 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5717709 | 0.84 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023123479-A1 | HEXAPEPTIDE, COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF HEXAPEPTIDE | 深圳市维琪科技股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-3170812-A1 | IMIDAZOLE COMPOUND AND LIPOSOME CONTAINING SAME | Fujifilm Corporation (JP) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016046409-A1 | NOVEL PEPTIDE DERIVATIVES AND USES THEREOF | NOSOPHARM (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-1613420-B1 | METHOD FOR SELECTIVELY BINDING A SUBSTRATE TO SORBENTS BY WAY OF AT LEAST BIVALENT BONDS | INSTRACTION GMBH (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-7612103-B2 | Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin | NABRIVA THERAPEUTICS AG (AT) | 2009-11-03 | — | — | US | disclosed |
| US-7612103-B2 | Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin | NABRIVA THERAPEUTICS AG (AT) | 2009-11-03 | — | — | US | disclosed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1534678-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBBIALS | NABRIVA THERAPEUTICS FORSCHUNG (AT) | 2007-10-31 | — | — | EP | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | CYP3A4 2436/4885SLC7A5 1953/4885HRH4 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.